Valerio Therapeutics ALVIO

VILLEJUIF, France, August 24, 2026--Regulatory News: Valerio Therapeutics (FR0010095596 - ALVIO), a biotechnology company pioneering next-generation precision-guided RNA therapeutics ("Valerio" or the "Company"), today announces the signing of a definitive share purchase agreement (the "SPA") and of the related contribution agreement (the "Contribution Agreement") for the acquisition of 100% of the share capital and voting rights of Etherna Immunotherapies NV ("Etherna") (the "Acquisition"), bas

VILLEJUIF, France, August 17, 2026--Regulatory News: Valerio Therapeutics (FR0010095596 - ALVIO), a biotechnology company pioneering next-generation precision-guided RNA therapeutics ("Valerio" or the "Company"), provides an update on the contemplated acquisition of 100% of the share capital of Etherna Immunotherapies NV ("Etherna") (the "Acquisition").

VILLEJUIF, France, July 16, 2026--Regulatory News: Valerio Therapeutics (FR0010095596 – ALVIO), a biotechnology company pioneering next-generation precision-guided RNA therapeutics ("Valerio" or the "Company"), today announces that it has entered into a binding term-sheet with Abivax SA ("Abivax"), setting out the principal terms of an exclusive worldwide research and development collaboration. The final terms remain subject to the signing of the definitive co-ownership and license agreement.

VILLEJUIF, France, July 01, 2026--Regulatory News: Valerio Therapeutics (FR0010095596 – ALVIO), a biotechnology company pioneering next-generation precision-guided RNA therapeutics ("Valerio" or the "Company"), today announces that it has signed a binding offer for the acquisition of 100% of the share capital of Etherna Immunotherapies NV ("Etherna") (the "Acquisition").

VILLEJUIF, France, June 16, 2026--Regulatory News: Valerio Therapeutics (FR0010095596 – ALVIO), a clinical-stage biotechnology company pioneering next-generation precision-guided therapeutics (the "Company"), today announces the appointment of Gilles Besin, Ph.D. as Chief Executive Officer by the Board of Directors, effective 1 July 2026, as well as the results of the votes at its shareholders’ general meeting held on 16 June 2026 (the "General Meeting").